1. Executive Session 6:00 – 6:15
   ● Discussion on Medicaid OBRA ’90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 6:15 – 6:20
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:20 – 6:30
   ● Updates

4. Medical Director Update 6:30 – 6:35
   ● Clinical Programs Update
   ● Prescriber Comments

5. Follow-up Items from Previous Meetings 6:35 – 6:50
   ● Benzodiazepines
   ● Buprenorphine & Buprenorphine/Naloxone (end of grandfathering)
   ● Oxycodone IR/Hydromorphone IR

6. RetroDUR/DUR 6:50 – 7:10
   ● Diazepam Daily Quantities/Prescribing for Alcohol Withdrawal
   ● Sovaldi® (sofosbuvir) in Hepatitis C

7. Clinical Update: Drug Reviews 7:10 – 7:50
   (Public comment prior to Board action)
   Abbreviated New Drug Reviews
     ● Harvoni® (ledipasvir-sofosbuvir) Oral Tablet (initial discussion, no PDL decision)
     ● Sitavig® (acyclovir) Buccal Tablet
   Full New Drug Reviews
     ● Myalept® (metreleptin) Vial for Subcutaneous Injection
     ● Zohydro® ER (hydrocodone bitartrate) Extended Release Oral Tablet (non-abuse deterrent formulation)
     ● Zontivity® (vorapaxar) Oral Tablet
8. Therapeutic Drug Classes – Periodic Review  7:50 – 8:00
   (Public comment prior to Board action)
   - Anticoagulants - Oral

9. Clinical Update: New/Updated Clinical Guidelines  8:00 – 8:00
   (Public comment prior to Board action)
   - None

10. New Managed Therapeutic Drug Classes  8:00 – 8:00
    (Public comment prior to Board action)
    - None

11. Review of Newly-Developed/Revised
    Clinical Coverage Criteria and/or Preferred Products
    8:00 – 8:10
    (Public comment prior to Board action)
    - Antidepressants – step therapy requirements for non-preferred agents
    - Kalydeco® (ivacaftor) Oral Tablet (additional approved genetic mutations)

    Updates for 1/1/2015
    - Testosterone: Topical

12. General Announcements  8:10 – 8:15
    Selected FDA Safety Alerts
    - Xolair® (omalizumab) - slightly higher risk of cardiovascular/cerebrovascular events

13. Adjourn  8:15